ArticleBMJ open2019

Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial).

Line Uhrenholt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.